Table 4 Multivariate analysis for TTNT.

From: Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin

Factors

 

Model 1

Model 2

Hazard ratio

95% CI

p-value

p-value*

Hazard ratio

95% CI

p-value

p-value*

Type of treatment regimen

ERd

1

 

0.143

0.151

1

 

0.431

0.432

EPd

0.713

0.453–1.121

  

0.801

0.460–1.393

  

Lymphocyte Free light chain score

0

1

 

< 0.001

< 0.001

    

1

2.395

1.236–4.639

      

2

4.069

2.063–8.026

      

Lymphocyte B2MG score

0

    

1

 

< 0.001

< 0.001

1

    

2.123

1.178–3.829

  

2

    

4.608

2.144–9.904

  

Prior regimen numbers

< 4

1

 

0.009

0.007

1

 

0.292

0.228

≥ 4

1.967

1.178–3.285

  

1.358

0.768–2.399

  

Prior use of daratumumab

No

1

 

0.021

0.005

1

 

< 0.001

< 0.001

Yes

1.627

1.075–2.463

  

3.247

1.974–5.343

  
  1. Multivariate analyses against TTNT in MM patients treated with elotuzumab were performed using the scoring system (model 1 and model 2) as factors. In model 1, we picked up the following factors: type of treatment regimen, WBC counts, lymphocyte free light chain score, number of prior regimens and prior use of daratumumab. In model 2, we picked up the following factors: type of treatment regimen, WBC counts, lymphocyte B2MG score, number of prior regimens and prior use of daratumumab. The Cox proportional hazard model was used to calculate the hazard ratio for each variable; the 95% CI and p-value are shown. *P-value after the bootstrapping process (1000 samples).
  2. TTNT, CI, ERd, EPd and B2MG. TTNT: time to next treatment; CI: confidence interval; ERd: elotuzumab, lenalidomide and dexamethasone regimen; EPd: elotuzumab, pomalidomide and dexamethasone regimen; B2MG: β2 microglobulin.
Back to article page